Last Updated : January 29, 2025
Details
Generic Name:
Acalabrutinib
Project Status:
Complete
Therapeutic Area:
Chronic Lymphocytic Leukemia (CLL)
Manufacturer:
AstraZeneca Canada Inc
Brand Name:
Calquence
Project Line:
Reimbursement Review
Project Number:
PC0211-000
Tumour Type:
Lymphoma
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
Recommendation Type:
Reimburse with clinical criteria and/or conditions
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 29, 2025